Price T Rowe Associates Inc. MD Buys 56,214 Shares of IVERIC bio, Inc. (NASDAQ:ISEE)

Price T Rowe Associates Inc. MD boosted its position in shares of IVERIC bio, Inc. (NASDAQ:ISEE – Get Rating) by 1.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,446,354 shares of the company’s stock after acquiring an additional 56,214 shares during the period. Price T Rowe Associates Inc. MD owned 2.85% of IVERIC bio worth $61,829,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in ISEE. Putnam Investments LLC raised its position in shares of IVERIC bio by 751.1% during the 3rd quarter. Putnam Investments LLC now owns 144,700 shares of the company’s stock valued at $2,596,000 after purchasing an additional 127,698 shares during the period. Parkman Healthcare Partners LLC bought a new position in shares of IVERIC bio in the third quarter worth about $897,000. Polar Asset Management Partners Inc. purchased a new stake in shares of IVERIC bio during the third quarter worth about $10,909,000. Quantamental Technologies LLC bought a new stake in IVERIC bio during the 3rd quarter valued at approximately $375,000. Finally, Laurion Capital Management LP lifted its holdings in IVERIC bio by 5.6% in the 3rd quarter. Laurion Capital Management LP now owns 52,871 shares of the company’s stock worth $949,000 after purchasing an additional 2,793 shares in the last quarter.

IVERIC bio Trading Up 5.2 %

ISEE opened at $22.69 on Tuesday. IVERIC bio, Inc. has a 12 month low of $8.85 and a 12 month high of $26.35. The company has a current ratio of 18.63, a quick ratio of 18.63 and a debt-to-equity ratio of 0.18. The stock has a 50-day moving average of $21.28 and a 200 day moving average of $20.17. The firm has a market cap of $3.11 billion, a P/E ratio of -14.93 and a beta of 1.09.

IVERIC bio (NASDAQ:ISEE – Get Rating) last announced its earnings results on Wednesday, March 1st. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.10). During the same period in the previous year, the firm posted ($0.29) earnings per share. As a group, research analysts forecast that IVERIC bio, Inc. will post -1.68 EPS for the current year.

Insiders Place Their Bets

In other news, SVP Christopher Paul Simms sold 2,368 shares of the stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $20.06, for a total value of $47,502.08. Following the sale, the senior vice president now owns 32,429 shares of the company’s stock, valued at $650,525.74. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, COO Keith Westby sold 3,480 shares of the firm’s stock in a transaction dated Tuesday, January 3rd. The shares were sold at an average price of $20.06, for a total value of $69,808.80. Following the transaction, the chief operating officer now owns 86,354 shares of the company’s stock, valued at approximately $1,732,261.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Christopher Paul Simms sold 2,368 shares of the business’s stock in a transaction dated Tuesday, January 3rd. The shares were sold at an average price of $20.06, for a total transaction of $47,502.08. Following the completion of the sale, the senior vice president now directly owns 32,429 shares of the company’s stock, valued at $650,525.74. The disclosure for this sale can be found here. Insiders sold 93,765 shares of company stock valued at $2,079,385 over the last three months. 2.70% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on ISEE shares. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of IVERIC bio in a report on Thursday, March 2nd. B. Riley lifted their price target on shares of IVERIC bio from $17.00 to $19.00 and gave the company a “neutral” rating in a report on Tuesday, February 21st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, IVERIC bio has an average rating of “Moderate Buy” and a consensus target price of $27.30.

About IVERIC bio

(Get Rating)

IVERIC bio, Inc operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R.